Dr. Amol Narang of Johns Hopkins Medicine serves as a key expert on the National Comprehensive Cancer Network guidelines panel for pancreatic adenocarcinoma.
His role is significant because these national guidelines standardize how physicians across the U.S. treat one of the most aggressive forms of cancer. By integrating radiation oncology into these protocols, the panel ensures a multidisciplinary approach to patient care.
Narang is an associate professor in the Johns Hopkins Department of Radiation Oncology and Molecular Sciences [1]. He is one of three radiation oncologists [1] appointed to the NCCN pancreatic adenocarcinoma guidelines panel, where he helps determine the best practices for treating the disease.
Based at the Johns Hopkins Hospital in Baltimore, Maryland, Narang specializes in gastrointestinal malignancies [1]. His clinical focus includes the treatment of pancreatic, hepatobiliary, colorectal, and gastric cancers, as well as retroperitoneal sarcoma [1].
Radiation oncology involves the use of high-energy particles or waves to destroy and shrink tumor cells. In the context of pancreatic cancer, this specialization is critical for managing tumors that may be surgically challenging or for treating the disease after an initial operation.
Narang's work combines academic research with direct patient care. As an associate professor, he contributes to the training of future oncologists while applying the latest evidence-based medicine to his clinical practice in Baltimore [1].
“Dr. Amol Narang serves as one of three radiation oncologists on the NCCN pancreatic adenocarcinoma guidelines panel.”
The inclusion of a limited number of radiation oncologists on the NCCN panel highlights the specialized nature of radiation therapy in pancreatic cancer treatment. Because these guidelines dictate the standard of care for thousands of patients, Narang's expertise directly influences the clinical pathways used by hospitals nationwide to improve survival rates for gastrointestinal malignancies.
